This cleared the path for efficacy testing in Alzheimer's patients
Breaking this loop requires understanding how it works
Key points The pathological basis of interstitial cystitis/bladder pain syndrome (IC/BPS) remains unclear, with several hypotheses suggesting potential mechanisms, including autoimmune inflammation, oxidative stress and urothelial dysfunction
BPC-157 (5 mg Vial): Standard / Gradual Approach (2 mL = 2.5 mg/mL) Reconstitute: Add 2.0 mL bacteriostatic water to the BPC-157 (5 mg) vial 2.5 mg/mL (2,500 mcg/mL)
BPC-157 is NOT suitable for individuals with: Active cancer (as it promotes new blood vessel growth)
Decreased stomach acid Atrophic gastritis Autoimmune pernicious anaemia Helicobacter pylori Gastrectomy, partial or complete Gastric bypass surgery (weight loss) Intestinal resection Partial or complete ileectomy Gastrointestinal neoplasms Malnutrition Eating disorders anorexia bulimia Inadequate diet Vegetarianism / veganism Malabsorption syndromes Alcoholism Crohns disease Coeliac disease (gluten enteropathy) Dipphyllobothrium infection blind loop syndrome diverticulosis inflammatory bowel disease small bowel overgrowth tropical sprue gastric irradiation ileal irradiation (bladder,cervix, uterus,prostate) Inborn errors of B12 metabolism Transcobalamin II deficiency Pancreatic exocrine insufficiency & Chronic pancreatitis Imerslund Gresbeck syndrome Zollinger Ellison Syndrome Bacterial overgrowth (small bowel) Fish tapeworm Advanced liver disease Drug induced causes Please note